Skip to main content
Premium Trial:

Request an Annual Quote

Genome Quebec Names Former Glaxo Wellcome Exec As CEO

NEW YORK, June 12 - Genome Quebec, the provincial arm of the Canadian genomics research organization Genome Canada, has appointed Paul L'Archevêque to the position of president and chief executive officer, the organization said Tuesday. 

L'Archevêque, a former vice president for marketing at Glaxo Wellcome, now GlaxoSmithKline, said in a statement he would strive to bridge the private and public sectors in raising money and awareness of genomics in Quebec. 

Genome Quebec was established in April with an initial grant from Genome Canada of $40 million Canadian ($26.2 million). The non-profit organization has a mission to promote genomics research and businesses in the province, and has awarded grants to five investigators to fund research projects at institutions in Quebec. 

In addition to the $26.2 million from Genome Canada, Genome Quebec also has a pledge from the Ministère de la Recherche, de la Science et de la Technologie du Québec over a 4 year period to provide an additional $26.2 million Canadian over the next four years. The organization is also seeking funding from universities and businesses in Quebec.

The organization's founding is part of a flurry of activity in Canada to stimulate its biotechnology and genomics sector. In February, Canada doubled the budget for Genome Canada to $195 million. 

Although the Genome Quebec is currently without a permanent home, by August 2002 the organization will have its headquarters on the campus of McGill University in Montreal.    
The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.